Targeting T cell costimulation in autoimmune disease.

Area of Science:

• Immunology
• Autoimmune Disease Pathogenesis
• Immunotherapy

Background:

• Autoimmune diseases arise from complex immune dysregulation.
• Understanding T cell activation is crucial for developing targeted therapies.
• Costimulatory molecules on T cells and antigen-presenting cells (APCs) play key roles in immune responses.

Purpose of the Study:

• To review the role of costimulatory molecules in T cell activation.
• To discuss current and potential therapeutic strategies targeting these molecules for autoimmune diseases.
• To explore how targeting costimulation can selectively modulate immune responses.

Main Methods:

• Review of existing literature on T cell costimulatory molecules.
• Analysis of the functions of key molecules such as B7-1, B7-2, CD28, CTLA-4, ICOS, PD-1, OX40, and CD40L.
• Examination of therapeutic approaches, primarily antibody-based blockade.

Main Results:

• Identified key costimulatory (CD28, ICOS, OX40, CD40L) and inhibitory (CTLA-4, PD-1) molecules involved in T cell activation.
• Highlighted that CD28 primarily activates naive T cells, while ICOS and OX40 act on memory cells.
• Noted that therapies often involve blocking these interactions using receptor-specific immunoglobulins (Ig).

Conclusions:

• Targeting costimulation pathways presents a viable strategy for treating autoimmune diseases.
• Therapeutic blockade of costimulatory molecules can selectively eliminate autoreactive T cells.
• This approach holds promise for preserving overall immune function while managing autoimmune conditions.